| Chemical Name |
SCH 58261 |
| CAS Number |
160098-96-4 |
| MDL Number |
MFCD00933778 |
| Molecular Formula |
C18H15N7O |
| Molecular Weight |
345.36 |
Introduction of 160098-96-4 :
SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively[1][2][3]. IC50 & Target: IC50: 15 nM (A2A receptor)[2] In Vitro: SCH 58261 (0 nM–10 µM; 7 days) decreases cell viability in a concentration-dependent in the NSCLC cell line H1975[4].
SCH58261 (25 μM; 72 hours) can inhibit the growth of CAF cells[5].
In Vivo: SCH 58261 (2 mg/kg; i.p.; daily; for 20 days) causes a decrease in the tumor burden in a NSCLC mouse model[5].
SCH 58261 (5 mg/kg; i.p.; 3 times; every 3 hours; 10 minutes before haloperidol) partially decreases the haloperidol-induced catalepsy and the increase in the PENK mRNA expression in both dorsolateral and ventrolateral parts of the striatum at all three examined levels[6].
SCH 58261 diminishes the parkinsonian-like muscle rigidity and potentiates the effect of L-DOPA in rat model[7].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
